CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation.
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Tessa Kerre, MD, PhD
University Hospital, Ghent
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Universitair Ziekenhuis Gent
Ghent, Oost-Vlaanderen, Belgium
- Zna Stuivenberg
Antwerp, Belgium
- Az Sint-Jan Brugge
Bruges, Belgium
- Cliniques Universitaires Saint Luc
Brussels, Belgium
- Institut Jules Bordet
Brussels, Belgium
- Universitair Ziekenhuis Brussel
Brussels, Belgium
- Université de Liège
Liège, Belgium
- Heilig Hart Ziekenhuis Roeselare
Roeselare, Belgium
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Oct 2016
- Primary completion
- 31 Dec 2021
- Completion
- 31 Dec 2021
- Last update posted
- 21 Dec 2022
- Registered enrollment
- 1
- Registry id
- NCT03067155
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.